Azenosertib is under clinical development by Zentalis Pharmaceuticals and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData, Phase II drugs for Epithelial Ovarian Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Azenosertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Azenosertib overview
Azenosertib (ZNC-3) is under development for the treatment solid tumors including relapsed or refractory osteosarcoma, platinum sensitive ovarian cancer, pancreatic cancer, recurrent uterine serous carcinoma (USC), endometrial cancer, metastatic colorectal cancer, platinum resistant ovarian cancer, PARPi resistant ovarian cancer, glioblastoma multiforme, triple-negative breast cancer, HER2-negative breast cancer, relapsed, refractory and secondary acute myeloid leukemia. It is administered orally as a tablet. The drug candidate acts by targeting WEE1.
It was also under development for the treatment of metastatic advanced breast cancer, non-small cell lung carcinoma, ovarian cancer, uterine cancer, peritoneal cancer and fallopian tube cancer
.
Zentalis Pharmaceuticals overview
Zentalis Pharmaceuticals is a biopharmaceutical company that discovers and develops small molecule drugs to treat cancers. Its lead product candidate is ZN-c3, a WEE1 inhibitor against uterine serous carcinoma, solid tumors, osteosarcoma and ovarian cancer. The company is also evaluating ZN-c5, an oral SERD (selective estrogen receptor degrader) for the treatment of breast cancer; ZN-d5, a BCL-2 (B-cell lymphoma 2) inhibitor targeting hematologic malignancies; and ZN-e4, an EGFR (epidermal growth factor receptor) inhibitor to treat non-small cell lung carcinoma. It works in collaboration with Pfizer Inc, Mayo Clinic and SciClone Pharmaceuticals Inc, among others. Zentalis Pharmaceuticals is headquartered in New York, the US.
For a complete picture of Azenosertib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
